These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 17706644)

  • 1. Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms.
    Halliday GM; McCann H
    Exp Neurol; 2008 Jan; 209(1):12-21. PubMed ID: 17706644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alteration in alpha-synuclein mRNA expression in Parkinson's disease.
    Kingsbury AE; Daniel SE; Sangha H; Eisen S; Lees AJ; Foster OJ
    Mov Disord; 2004 Feb; 19(2):162-70. PubMed ID: 14978671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parkinson's disease genetic mutations increase cell susceptibility to stress: mutant alpha-synuclein enhances H2O2- and Sin-1-induced cell death.
    Jiang H; Wu YC; Nakamura M; Liang Y; Tanaka Y; Holmes S; Dawson VL; Dawson TM; Ross CA; Smith WW
    Neurobiol Aging; 2007 Nov; 28(11):1709-17. PubMed ID: 16978743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. alpha-Synuclein is colocalized with 14-3-3 and synphilin-1 in A53T transgenic mice.
    Shirakashi Y; Kawamoto Y; Tomimoto H; Takahashi R; Ihara M
    Acta Neuropathol; 2006 Dec; 112(6):681-9. PubMed ID: 16957925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of alpha-synuclein immunoreactive astrocytes in the forebrain parallels stages of intraneuronal pathology in sporadic Parkinson's disease.
    Braak H; Sastre M; Del Tredici K
    Acta Neuropathol; 2007 Sep; 114(3):231-41. PubMed ID: 17576580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nuclear and neuritic distribution of serine-129 phosphorylated alpha-synuclein in transgenic mice.
    Schell H; Hasegawa T; Neumann M; Kahle PJ
    Neuroscience; 2009 Jun; 160(4):796-804. PubMed ID: 19272424
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gelsolin co-occurs with Lewy bodies in vivo and accelerates α-synuclein aggregation in vitro.
    Welander H; Bontha SV; Näsström T; Karlsson M; Nikolajeff F; Danzer K; Kostka M; Kalimo H; Lannfelt L; Ingelsson M; Bergström J
    Biochem Biophys Res Commun; 2011 Aug; 412(1):32-8. PubMed ID: 21798243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective detection, quantification, and subcellular location of alpha-synuclein aggregates with a protein aggregate filtration assay.
    Kramer ML; Behrens C; Schulz-Schaeffer WJ
    Biotechniques; 2008 Mar; 44(3):403-11. PubMed ID: 18361794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The progression of pathology in Parkinson's disease.
    Halliday GM; McCann H
    Ann N Y Acad Sci; 2010 Jan; 1184():188-95. PubMed ID: 20146698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synucleins and their relationship to Parkinson's disease.
    von Bohlen Und Halbach O
    Cell Tissue Res; 2004 Oct; 318(1):163-74. PubMed ID: 15503152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spinal cord lesions in sporadic Parkinson's disease.
    Del Tredici K; Braak H
    Acta Neuropathol; 2012 Nov; 124(5):643-64. PubMed ID: 22926675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relationship between alpha-synuclein and Parkinson's disease].
    Nishioka K; Hattori N
    Brain Nerve; 2007 Aug; 59(8):825-30. PubMed ID: 17713118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Controlling the mass action of alpha-synuclein in Parkinson's disease.
    Kim C; Lee SJ
    J Neurochem; 2008 Oct; 107(2):303-16. PubMed ID: 18691382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Silver stainings distinguish Lewy bodies and glial cytoplasmic inclusions: comparison between Gallyas-Braak and Campbell-Switzer methods.
    Uchihara T; Nakamura A; Mochizuki Y; Hayashi M; Orimo S; Isozaki E; Mizutani T
    Acta Neuropathol; 2005 Sep; 110(3):255-60. PubMed ID: 16003542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. α-Synuclein and Lewy pathology in Parkinson's disease.
    Kalia LV; Kalia SK
    Curr Opin Neurol; 2015 Aug; 28(4):375-81. PubMed ID: 26110807
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aggregation-defective alpha-synuclein mutants inhibit the fibrillation of Parkinson's disease-linked alpha-synuclein variants.
    Koo HJ; Choi MY; Im H
    Biochem Biophys Res Commun; 2009 Aug; 386(1):165-9. PubMed ID: 19501571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in lysosomal and proteasomal markers in Parkinson's disease: relationship to alpha-synuclein inclusions.
    Chu Y; Dodiya H; Aebischer P; Olanow CW; Kordower JH
    Neurobiol Dis; 2009 Sep; 35(3):385-98. PubMed ID: 19505575
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.